Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

The Shell announced a quarterly dividend

7/27/23 SHEL

RESС reported for 6 months of 2023 by RAS

7/27/23 RZSB

Magnit opened in Moscow new superstore

7/27/23 MGNT

VTB reported for 6 months of 2023 by IFRS

7/27/23 VTBR

Shell has reported for 6 months of 2023

7/27/23 SHEL

VK is creating a new ticketing service and plans to embed it into VKontakte

7/27/23 VKCO

Rosseti Kuban reported for 6 months of 2023 by RAS

7/27/23 KUBE

Lenta may buy a competitor in the Urals

7/27/23 LENT

Phosagro plans to double fertilizer supplies to Africa

7/27/23 PHOR

FEK reported for 6 months of 2023 under RAS

7/27/23 DVEC